JP2001504093A - 融合性リポソーム組成物および方法 - Google Patents

融合性リポソーム組成物および方法

Info

Publication number
JP2001504093A
JP2001504093A JP51862998A JP51862998A JP2001504093A JP 2001504093 A JP2001504093 A JP 2001504093A JP 51862998 A JP51862998 A JP 51862998A JP 51862998 A JP51862998 A JP 51862998A JP 2001504093 A JP2001504093 A JP 2001504093A
Authority
JP
Japan
Prior art keywords
liposome
hydrophilic polymer
lipid
composition
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP51862998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001504093A5 (enExample
Inventor
ジェイ． マーティン，フランシス
ザリプスキー，サミュエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of JP2001504093A publication Critical patent/JP2001504093A/ja
Publication of JP2001504093A5 publication Critical patent/JP2001504093A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
JP51862998A 1996-10-11 1997-10-10 融合性リポソーム組成物および方法 Ceased JP2001504093A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2826996P 1996-10-11 1996-10-11
US60/028,269 1996-10-11
PCT/US1997/018838 WO1998016202A2 (en) 1996-10-11 1997-10-10 Fusogenic liposome composition and method

Publications (2)

Publication Number Publication Date
JP2001504093A true JP2001504093A (ja) 2001-03-27
JP2001504093A5 JP2001504093A5 (enExample) 2005-06-16

Family

ID=21842486

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51862998A Ceased JP2001504093A (ja) 1996-10-11 1997-10-10 融合性リポソーム組成物および方法

Country Status (15)

Country Link
US (1) US5891468A (enExample)
EP (1) EP0932391B1 (enExample)
JP (1) JP2001504093A (enExample)
AT (1) ATE232086T1 (enExample)
AU (1) AU715063B2 (enExample)
BR (1) BR9712230A (enExample)
CA (1) CA2267904C (enExample)
DE (1) DE69718924T2 (enExample)
DK (1) DK0932391T3 (enExample)
ES (1) ES2191833T3 (enExample)
HK (1) HK1047550A1 (enExample)
IL (1) IL129292A0 (enExample)
PT (1) PT932391E (enExample)
TW (1) TW520297B (enExample)
WO (1) WO1998016202A2 (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542341A (ja) * 1999-04-20 2002-12-10 ザ ユニバーシティ オブ ブリティッシュ コロンビア カチオン性ｐｅｇ脂質および使用方法。
JP2008239631A (ja) * 1996-11-12 2008-10-09 Regents Of The Univ Of California インビボ送達に有効な、脂質−核酸複合体の安定な製剤の調製
JP2008542500A (ja) * 2005-05-31 2008-11-27 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ 遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
WO2011025036A1 (ja) 2009-08-31 2011-03-03 ナノキャリア株式会社 粒子組成物及びこれを有する医薬組成物
JP2013529638A (ja) * 2010-06-19 2013-07-22 ウェスタン ユニバーシティ オブ ヘルス サイエンス Ｐｅｇ化リポソーム封入糖ペプチド抗生物質の新規製剤
US8574601B2 (en) 2010-02-05 2013-11-05 Nanocarrier Co., Ltd. Sustained-release polymer micelle disruptable by HDL
JP2014519493A (ja) * 2011-05-12 2014-08-14 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド ポリマー共役脂質を含むリポソームおよび関連用途
US9271929B2 (en) 2008-11-25 2016-03-01 École Polytechnique Fédérale De Lausanne (Epfl) Block copolymers and uses thereof
JP2018519347A (ja) * 2015-07-09 2018-07-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 融合性リポソーム被覆多孔質ケイ素ナノ粒子
WO2023210671A1 (ja) * 2022-04-26 2023-11-02 京セラ株式会社 共重合体、高分子膜、測定用装置および測定用担体

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US20070036722A1 (en) * 1996-10-28 2007-02-15 Pal Rongved Separation processes
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
US6426086B1 (en) * 1998-02-03 2002-07-30 The Regents Of The University Of California pH-sensitive, serum-stable liposomes
US6372720B1 (en) 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
US6936729B2 (en) * 1998-05-16 2005-08-30 Mirus Bio Corporation Compound containing a labile disulfide bond
US7087770B2 (en) 1998-05-16 2006-08-08 Mirus Bio Corporation Compound containing a labile disulfide bond
CA2346879A1 (en) 1998-09-16 2000-04-27 Alza Corporation Liposome-entrapped topoisomerase inhibitors
WO2000035422A2 (en) * 1998-12-18 2000-06-22 Hadasit Medical Research Services & Development Ltd. Method of administering a compound to multi-drug resistant cells
US6379698B1 (en) * 1999-04-06 2002-04-30 Isis Pharmaceuticals, Inc. Fusogenic lipids and vesicles
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
HUP0201425A3 (en) * 1999-04-23 2006-07-28 Hadasit Med Res Service Conjugate having a cleavable linkage for use in a liposome
IL146047A0 (en) * 1999-04-23 2002-07-25 Alza Corp Releasable linkage and compositions containing same
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
AUPQ014699A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
EP1180242A1 (de) * 1999-05-27 2002-02-20 Zeptosens AG Polymer-enthaltendes vesikel und darauf basierte sensor-nachweisverfahren
PT1198490E (pt) * 1999-07-14 2006-06-30 Alza Corp Lipopolimeros neutros e composicoes liposomais que contem os mesmos
AU7868400A (en) 1999-10-08 2001-04-23 Alza Corporation Neutral-cationic lipid for nucleic acid and drug delivery
US20040197390A1 (en) * 2001-05-29 2004-10-07 Shi-Kun Huang Neutral-cationic lipid for systemic delivery of factor VIII gene
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6916488B1 (en) * 1999-11-05 2005-07-12 Biocure, Inc. Amphiphilic polymeric vesicles
AU1776801A (en) * 1999-11-24 2001-06-04 Liposome Company, Inc., The Modular targeted liposomal delivery system
WO2001041738A2 (en) * 1999-12-10 2001-06-14 Celator Technologies Inc. Lipid carrier compositions with protected surface reactive functions
DE60110057T2 (de) * 2000-01-28 2005-09-08 Alza Corp., Mountain View Liposomen enthaltend eine eingeschlossene verbindung in übersattigter lösung
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
WO2001080900A2 (en) * 2000-04-20 2001-11-01 The University Of British Columbia Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
IL153218A0 (en) 2000-06-02 2003-07-06 Univ Texas Ethylenedicysteine (ec) -drug conjugates
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
AU2002225878A1 (en) * 2000-11-02 2002-05-15 Smith Kline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
US6613280B2 (en) 2001-03-20 2003-09-02 Therox, Inc. Disposable cartridge for producing gas-enriched fluids
US20030003114A1 (en) * 2001-03-22 2003-01-02 Pan Xing Qing Enzyme-based anti-cancer compositions and methods
HUP0303616A3 (en) * 2001-03-26 2006-07-28 Alza Corp Mountain View Liposome composition for improved intracellular delivery of a therapeutic agent
JP2004535388A (ja) * 2001-04-30 2004-11-25 ターゲティッド ジェネティクス コーポレイション 脂質含有薬物送達複合体およびそれらの生成方法
EP3231445A1 (en) * 2001-05-18 2017-10-18 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050233997A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20050288242A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US20050158735A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US20050196765A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) * 2001-05-18 2005-09-15 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
WO2002100317A2 (en) 2001-05-25 2002-12-19 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
US6939564B2 (en) * 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
JP2005527639A (ja) 2001-11-02 2005-09-15 インサート セラピューティクス インコーポレイテッド Ｒｎａ干渉の治療的利用のための方法及び組成物
GB0129121D0 (en) * 2001-12-05 2002-01-23 Ic Vec Ltd Compound
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003216445A1 (en) * 2002-02-27 2003-09-09 The Medical College Of Ohio Therapeutic methods for acute myeloid leukemia
US7018655B2 (en) * 2002-03-18 2006-03-28 Labopharm, Inc. Amphiphilic diblock, triblock and star-block copolymers and their pharmaceutical compositions
US20030198664A1 (en) * 2002-03-29 2003-10-23 Sullivan Sean Michael Lipid mediated screening of drug candidates for identification of active compounds
WO2004007662A2 (en) * 2002-04-23 2004-01-22 The Research Foundation Of State University Of New York Polymer surfactants for gene therapy applications
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
JP3415131B1 (ja) * 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
US20040093198A1 (en) * 2002-11-08 2004-05-13 Carbon Design Systems Hardware simulation with access restrictions
US7910661B2 (en) † 2003-01-06 2011-03-22 Nektar Therapeutics Thiol-selective water-soluble polymer derivatives
JPWO2004063216A1 (ja) * 2003-01-10 2006-06-15 アステラス製薬株式会社 血中滞留および癌組織特異的薬物送達のためのコンジュゲート
WO2004078121A2 (en) * 2003-02-28 2004-09-16 Alza Coporation Liposome composition for reduction of liposome-induced complement activation
JP2007524604A (ja) * 2003-03-31 2007-08-30 アルザ・コーポレーシヨン 非対称の脂質被膜を有する脂質粒子およびその製造方法
EP1628637A2 (en) * 2003-05-30 2006-03-01 Alza Corporation Method of pulmonary administration of an agent
US8846079B1 (en) * 2004-12-01 2014-09-30 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US11324698B2 (en) * 2003-08-28 2022-05-10 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
BRPI0418670B1 (pt) * 2003-08-29 2015-10-20 Univ Newcastle Res Ass método de separação de partículas sólidas de uma suspensão comprendendo um líquido e método decontrole da consolidação de um leito de partículas sólidas dentro de um líquido.
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
US20050175683A1 (en) * 2003-10-24 2005-08-11 Yuanpeng Zhang Preparation of lipid particles
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
JP2007520481A (ja) * 2004-01-15 2007-07-26 アルザ・コーポレーシヨン 治療薬を送達するためのリポソーム組成物
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US7985417B2 (en) * 2004-10-08 2011-07-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of lipid structure preparation
EP1854807A4 (en) * 2005-02-18 2009-04-01 Univ Tokushima A LIPID DERIVATIVE CONTAINING A POLYOXYALKYLENE CHAIN AND A LIPID FILM STRUCTURE CONTAINING SUCH A DERIVATIVE
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
KR20080042045A (ko) * 2005-05-23 2008-05-14 에스디지,인코포레이티드 포유동물로의 인터페론 전달용 지질 구조물
ES2798263T3 (es) 2005-12-08 2020-12-10 Insmed Inc Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
US8808681B2 (en) 2006-06-05 2014-08-19 Massachusetts Institute Of Technology Crosslinked, degradable polymers and uses thereof
US20080031883A1 (en) * 2006-07-13 2008-02-07 Torchilin Vladimir P Condition-dependent, multiple target delivery system
US8343539B2 (en) * 2006-07-14 2013-01-01 Regents Of The University Of Minnesota Compounds that bind α5β1 integrin and methods of use
EP2046266A4 (en) 2006-07-21 2009-11-04 Massachusetts Inst Technology ENDMODICIFIED POLY (BETA AMINO ESTER) AND ITS USE
US20080213349A1 (en) * 2006-09-11 2008-09-04 Deepak Ramesh Thakker Liposome Complexes Containing Pharmaceutical Agents and Methods
MX2009003092A (es) * 2006-09-22 2009-05-08 Labopharm Inc Composiciones y metodos para suministro de farmaco dirigido a ph.
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
WO2009006311A2 (en) * 2007-06-29 2009-01-08 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
WO2009091531A2 (en) * 2008-01-16 2009-07-23 The General Hospital Corporation Uniform-sized, multi-drug carrying and photosensitive liposomes for advance drug delivery
WO2009154688A1 (en) * 2008-05-28 2009-12-23 President And Fellows Of Harvard College A pre-fabricated electron microscopy grid for monolayer purification and methods and kits therefor
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2310440A4 (en) * 2008-07-10 2013-06-05 Serina Therapeutics Inc POLYOXAZOLINES WITH INTERNAL END GROUPS, POLYOXAZOLINES MANUFACTURED FROM PROTECTED INITIAL GROUPS AND CORRESPONDING COMPOUNDS
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
EP2230515B1 (en) * 2009-03-16 2014-12-17 Agilent Technologies, Inc. Passivation of surfaces after ligand coupling
CA3042927C (en) * 2009-05-05 2022-05-17 Arbutus Biopharma Corporation Lipid compositions for the delivery of therapeutic agents
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
WO2011017297A2 (en) 2009-08-03 2011-02-10 The University Of North Carolina At Chapel Hill Biodegradable delivery system complexes for the delivery of bioactive compounds
SI2506857T1 (en) 2009-12-01 2018-08-31 Translate Bio, Inc. Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
WO2011140254A1 (en) 2010-05-04 2011-11-10 Adimab, Llc Antibodies against epidermal growth factor receptor (egfr) and uses thereof
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
CA2831392C (en) 2011-03-28 2020-04-28 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
US8883989B2 (en) 2011-10-18 2014-11-11 Regents Of The University Of Minnesota Fractalkine binding polynucleotides and methods of use
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
EP3536787A1 (en) 2012-06-08 2019-09-11 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof
WO2014015027A1 (en) 2012-07-18 2014-01-23 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
CN102920658B (zh) * 2012-11-02 2015-01-21 艾韦特(溧阳)医药科技有限公司 与glp-1类似物和聚乙二醇结合的脂质体及其制备方法
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
EP2968145A1 (en) * 2013-03-13 2016-01-20 Mallinckrodt LLC Modified docetaxel liposome formulations
KR102311614B1 (ko) 2013-03-14 2021-10-08 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
WO2015013510A1 (en) 2013-07-25 2015-01-29 Ecole Polytechnique Federale De Lausanne Epfl High aspect ratio nanofibril materials
EP3574923A1 (en) 2013-10-22 2019-12-04 Translate Bio, Inc. Mrna therapy for phenylketonuria
ES3032935T3 (en) 2013-10-22 2025-07-29 Translate Bio Inc Lipid formulations for delivery of messenger rna
ES2707966T3 (es) 2013-10-22 2019-04-08 Translate Bio Inc Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
KR102415811B1 (ko) 2014-01-31 2022-07-04 팩터 바이오사이언스 인크. 핵산 제조 및 송달을 위한 방법 및 산물
US20170173005A1 (en) 2014-03-27 2017-06-22 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
CN106456744A (zh) 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
EP4729528A3 (en) 2014-04-25 2026-06-24 Translate Bio, Inc. Methods for purification of messenger rna
MX384843B (es) 2014-05-15 2025-03-14 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
WO2015184256A2 (en) 2014-05-30 2015-12-03 Shire Human Genetic Therapies, Inc. Biodegradable lipids for delivery of nucleic acids
KR102559979B1 (ko) 2014-06-24 2023-07-25 샤이어 휴먼 지네틱 테라피즈 인크. 핵산의 전달용 입체화학적으로 풍부한 조성물
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
CN104546722B (zh) * 2015-02-10 2017-05-24 中国医学科学院医药生物技术研究所 米铂脂质体和制法
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
RS64331B1 (sr) 2015-06-19 2023-08-31 Massachusetts Inst Technology Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
CN108289845A (zh) 2015-09-14 2018-07-17 维吉思康科技公司 皮下、舌下和口服治疗用空间稳定载体、用于治疗哺乳动物的组合物和方法
US10517823B1 (en) * 2016-08-10 2019-12-31 Verily Life Sciences Llc ROS—responsive liposomes for specific targeting
US10583083B1 (en) 2016-08-10 2020-03-10 Verily Life Sciences Llc ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages
IL264439B2 (en) 2016-08-17 2024-08-01 Factor Bioscience Inc non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
BR112019022016A2 (pt) * 2017-04-19 2020-05-12 Apa- Advanced Technologies Ltd. Lipossomas fusogênicos, composições, kits e uso dos mesmos no tratamento do câncer
IL270631B2 (en) 2017-05-16 2024-03-01 Translate Bio Inc Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
EP3700965A1 (en) 2017-10-27 2020-09-02 Massachusetts Institute of Technology Poly (beta-amino esters) and uses thereof
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
EP3787602A4 (en) 2018-05-02 2022-03-23 Insmed Incorporated PROCESS FOR THE MANUFACTURE OF LIPOSOMAL DRUG FORMULATIONS
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
WO2020084623A2 (en) * 2018-10-24 2020-04-30 Apa- Advanced Technologies Ltd. Fusogenic liposomes for selective imaging of tumor cells
AU2019366996A1 (en) 2018-10-26 2021-05-27 Massachusetts Institute Of Technology Polymer-lipids and compositions
AU2019384557B2 (en) 2018-11-21 2025-07-17 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
CA3155003A1 (en) 2019-09-20 2021-03-25 Translate Bio, Inc. Mrna encoding engineered cftr
EP4305088A1 (en) 2021-03-09 2024-01-17 Massachusetts Institute of Technology Branched poly(-amino esters) for the delivery of nucleic acids
AU2022270670A1 (en) 2021-05-05 2023-11-30 Nejat Duzgunes Liposome-encapsulated corticosteriods inhibit sars-cov-2 replication and reduces lung inflammation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136095A (en) * 1987-05-19 1992-08-04 Syntex (U.S.A.) Inc. Reversible agglutination mediators
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
JPH07173079A (ja) * 1992-12-22 1995-07-11 Nippon Oil & Fats Co Ltd 両親媒性ポリエチレングリコール誘導体および用途
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008239631A (ja) * 1996-11-12 2008-10-09 Regents Of The Univ Of California インビボ送達に有効な、脂質−核酸複合体の安定な製剤の調製
JP2002542341A (ja) * 1999-04-20 2002-12-10 ザ ユニバーシティ オブ ブリティッシュ コロンビア カチオン性ｐｅｇ脂質および使用方法。
JP2008542500A (ja) * 2005-05-31 2008-11-27 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ 遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
US9505867B2 (en) 2005-05-31 2016-11-29 Ecole Polytechmique Fédérale De Lausanne Triblock copolymers for cytoplasmic delivery of gene-based drugs
US9271929B2 (en) 2008-11-25 2016-03-01 École Polytechnique Fédérale De Lausanne (Epfl) Block copolymers and uses thereof
US10335499B2 (en) 2008-11-25 2019-07-02 École Polytechnique Fédérale De Lausanne (Epfl) Block copolymers and uses thereof
US9415059B2 (en) 2009-08-31 2016-08-16 Nanocarrier Co., Ltd. Particulate composition and pharmaceutical composition containing the same
KR20120083280A (ko) 2009-08-31 2012-07-25 나노캐리어 가부시키가이샤 입자 조성물 및 이를 가진 의약 조성물
EP3150194A1 (en) 2009-08-31 2017-04-05 NanoCarrier Co., Ltd. Particle composition and medicinal composition comprising same
WO2011025036A1 (ja) 2009-08-31 2011-03-03 ナノキャリア株式会社 粒子組成物及びこれを有する医薬組成物
US8574601B2 (en) 2010-02-05 2013-11-05 Nanocarrier Co., Ltd. Sustained-release polymer micelle disruptable by HDL
JP2013529638A (ja) * 2010-06-19 2013-07-22 ウェスタン ユニバーシティ オブ ヘルス サイエンス Ｐｅｇ化リポソーム封入糖ペプチド抗生物質の新規製剤
JP2014519493A (ja) * 2011-05-12 2014-08-14 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド ポリマー共役脂質を含むリポソームおよび関連用途
JP2018519347A (ja) * 2015-07-09 2018-07-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 融合性リポソーム被覆多孔質ケイ素ナノ粒子
WO2023210671A1 (ja) * 2022-04-26 2023-11-02 京セラ株式会社 共重合体、高分子膜、測定用装置および測定用担体

Also Published As

Publication number Publication date
EP0932391A2 (en) 1999-08-04
DE69718924D1 (de) 2003-03-13
US5891468A (en) 1999-04-06
CA2267904C (en) 2005-08-02
DE69718924T2 (de) 2003-12-04
PT932391E (pt) 2003-06-30
HK1047550A1 (en) 2003-02-28
TW520297B (en) 2003-02-11
CA2267904A1 (en) 1998-04-23
AU4987897A (en) 1998-05-11
BR9712230A (pt) 2000-01-25
ES2191833T3 (es) 2003-09-16
WO1998016202A3 (en) 1998-07-16
WO1998016202A2 (en) 1998-04-23
IL129292A0 (en) 2000-02-17
EP0932391B1 (en) 2003-02-05
ATE232086T1 (de) 2003-02-15
DK0932391T3 (da) 2003-05-26
AU715063B2 (en) 2000-01-13

Similar Documents

Publication Publication Date Title
US5891468A (en) Fusogenic liposome compositions and method
US6224903B1 (en) Polymer-lipid conjugate for fusion of target membranes
US6936272B2 (en) 10139483Therapeutic liposome composition and method of preparation
US7060291B1 (en) Modular targeted liposomal delivery system
US7108863B2 (en) Liposome composition for improved intracellular delivery of a therapeutic agent
US6897196B1 (en) pH sensitive lipids based on ortho ester linkers, composition and method
EP1156783B1 (en) Encapsulation of bioactive complexes in liposomes
Carrion et al. Preparation of long-circulating immunoliposomes using PEG–cholesterol conjugates: effect of the spacer arm between PEG and cholesterol on liposomal characteristics
AU2002305094A1 (en) Liposome composition for improved intracellular delivery of a therapeutic agent
JP2001503396A (ja) 治療用リポソーム組成物および方法
AU4096200A (en) Cationic peg-lipids and methods of use
JP2002525270A (ja) トランスフェクションのためのコンデンスされたプラスミド−リポソーム複合体
KR20020063875A (ko) 핵산 및 약물 전달용 중성-양이온성 지질
Hodenius et al. Biotinylated stealth® magnetoliposomes
Fenske et al. Cationic poly (ethyleneglycol) lipids incorporated into pre-formed vesicles enhance binding and uptake to BHK cells
EP1231895B1 (en) Modular targeted liposomal delivery system
US7741431B2 (en) Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
JP2006519262A (ja) リポソームにより誘導される補体活性化の減少のためのリポソーム組成物
EP1214935A2 (en) Fusogenic liposome composition and method
AU736055B2 (en) Fusogenic liposome composition and method
AU761204B2 (en) Fusogenic liposome composition and method
CA2505445A1 (en) Fusogenic liposome composition and method
US20240033374A1 (en) Nano-structural Protein Degradation Tool, Use, and Preparation Method thereof, and Lipid-based Protein Degradation Tool, Use, and Preparation Method thereof
MXPA99003336A (en) Fusogenic liposome composition and method
MXPA01008804A (en) Encapsulation of bioactive complexes in liposomes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041008

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041008

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20061227

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20061227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080610

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20081104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090106